CMEs for Neurologists in 2018

Featured CMEs for neurology, neuro-ophthalmology, neuroradiology, and neurosurgery, as well as a range of other topics.

Related Videos
Related Content

Efgartigimod Effective Across Subgroups, FDA to Hold AdComm Meeting on SRP-9001, Reboxetine Demonstrates Positive Effect on Obstructive Sleep Apnea

March 25th 2023

Episode 85: Impact of Narcolepsy on Social Relationship Health in Adolescents

March 24th 2023

Depression History Shows No Impact on Efficacy, Safety of Solriamfetol in Treating Obstructive Sleep Apnea, Narcolepsy

March 24th 2023

Special Episode: Trofinetide Approved for Rett Syndrome

March 13th 2023

Myasthenia Agent Zilucoplan Continues to Show Positive Efficacy in Long-Term Extension

March 23rd 2023

Consensus Considerations Developed for SRP-9001 Adverse Event Management in DMD

March 23rd 2023

Efgartigimod Effective Across Subgroups, FDA to Hold AdComm Meeting on SRP-9001, Reboxetine Demonstrates Positive Effect on Obstructive Sleep Apnea

March 25th 2023

Episode 85: Impact of Narcolepsy on Social Relationship Health in Adolescents

March 24th 2023

Depression History Shows No Impact on Efficacy, Safety of Solriamfetol in Treating Obstructive Sleep Apnea, Narcolepsy

March 24th 2023

Special Episode: Trofinetide Approved for Rett Syndrome

March 13th 2023

Myasthenia Agent Zilucoplan Continues to Show Positive Efficacy in Long-Term Extension

March 23rd 2023

Consensus Considerations Developed for SRP-9001 Adverse Event Management in DMD

March 23rd 2023

Efgartigimod Effective Across Subgroups, FDA to Hold AdComm Meeting on SRP-9001, Reboxetine Demonstrates Positive Effect on Obstructive Sleep Apnea

March 25th 2023

Episode 85: Impact of Narcolepsy on Social Relationship Health in Adolescents

March 24th 2023

Depression History Shows No Impact on Efficacy, Safety of Solriamfetol in Treating Obstructive Sleep Apnea, Narcolepsy

March 24th 2023

Special Episode: Trofinetide Approved for Rett Syndrome

March 13th 2023

Myasthenia Agent Zilucoplan Continues to Show Positive Efficacy in Long-Term Extension

March 23rd 2023

Consensus Considerations Developed for SRP-9001 Adverse Event Management in DMD

March 23rd 2023
© 2023 MJH Life Sciences

All rights reserved.